AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30895244
Drug: 0.2 mL
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL insemination volume
Trial: 30896447
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^7 cells)
Trial: 30896447
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^8 cells)
Trial: 30896447
Drug: CART-BCMA infusions
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CART-BCMA infusions with or without lymphodepleting chemotherapy
Trial: 30898821
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Trial: 30898821
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Trial: 30899297
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of subcutaneous collateral vessel of the chest/abdominal wall
Trial: 30900412
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose challenge test results
Trial: 30900412
Drug: Time interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time interaction for insulin
Trial: 30901867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4 mg ondansetron and 4 mg dexamethasone
Trial: 30902361
Drug: Intranasal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hydromorphone (0.03 mg/kg initial dose, additional 0.015 mg/kg if needed)
Trial: 30902361
Drug: Intranasal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hydromorphone
Trial: 30902915
Drug: Paclitaxel (chemotherapy)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (chemotherapy)
Trial: 30903275
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg orally QD)
Trial: 30903661
Drug: Plans to
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plans to keep pills
Trial: 30903661
Drug: Plans to
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plans to dispose of pills
Trial: 30904021
Drug: myo-inositol (1.75 g/day),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day), glucomannan (4 g/day) for 3 months
Trial: 30904854
Drug: Internet-based, therapist-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based, therapist-guided cognitive-behavioural therapy (CBT) for BDD, 12-week treatment consisting of eight treatment modules.
Trial: 30904859
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT lung cancer screening
Trial: 30904869
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (SCRT) at dose levels of 6Gy×5F, 7Gy×5F, 8Gy×5F followed by four cycles of modified FOLFOX6 (mFOLFOX6) chemotherapy as neoadjuvant therapy.
Trial: 30904980
Drug: Pralatrexate IV
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate IV 30 mg/m²
Trial: 30905354
Drug: RFA for
RxNorm normalized name: Rfaudraksha resin
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFA for treatment of flat USLs
Trial: 30906694
Drug: Gambling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gambling intervention only (G only)
Trial: 30906694
Drug: Gambling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gambling intervention with mental health intervention (G + MH)
Trial: 30907259
Drug: EndoAnchor implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoAnchor implants with good penetration
Trial: 30907453
Drug: Anti-staphylococcal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-staphylococcal treatment
Trial: 30908927
Drug: Combined Forced
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response
Trial: 30909832
Drug: Ranolazine 500
RxNorm normalized name: ranolazine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 500 mg
Trial: 30909832
Drug: Ranolazine 1000
RxNorm normalized name: ranolazine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000 mg
Trial: 30910221
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone treatment (mean dose: 0.4mg/kg/week at month 0, M12, M24; 0.3mg/kg/week at M36)
Trial: 30910221
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone treatment
Trial: 30910890
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing guidelines for antituberculosis drugs
Trial: 30910890
Drug: Dose increment
RxNorm normalized name: Urinary concrement solvents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increment of one fixed-dose combination (FDC) tablet for weight bands of 30 to 37 and 38 to 54 kg
Trial: 30910890
Drug: Different formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different formulations of rifampin and isoniazid
Trial: 30910890
Drug: Current dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current dosing guidelines
Trial: 30910890
Drug: Adding one
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding one FDC tablet to current weight band-based dosing
Trial: 30910891
Drug: Intravenous rifampin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rifampin, 8 mg/kg for <14 days PNA, 15 mg/kg for ≥14 days PNA, administered once daily
Trial: 30910892
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral fluconazole
Trial: 30911064
Drug: Prenatal acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal acetaminophen use (any use)
Trial: 30911064
Drug: No prenatal
RxNorm normalized name: Vitafol-Nano Prenatal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prenatal acetaminophen use
Trial: 30911405
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (RIC) administered by EMS paramedics using the autoRIC® device, 4 cycles of 5-min inflation and 5-min deflation of an upper arm cuff
Trial: 30911655
Drug: Adjuvant PIPAC-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant PIPAC-directed therapy with oxaliplatin (92 mg/m2)
Trial: 30911655
Drug: Adjuvant PIPAC-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant PIPAC-directed therapy
Trial: 30911655
Drug: PIPAC-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC-directed therapy
Trial: 30911657
Drug: ABP (Abraxane™)
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP (Abraxane™) administered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) at escalating doses from 35 to 140 mg/m², with three treatments at 4-week intervals.
Trial: 30911656
Drug: Pressurized IntraPeritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using doxorubicin (1.5 mg/m²) in series of three procedures
Trial: 30911656
Drug: Pressurized IntraPeritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Trial: 30911663
Drug: PIPAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC with oxaliplatin (starting dose 45 mg/m)
Trial: 30911664
Drug: Oxaliplatin administered
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin administered by the intraperitoneal route (PIPAC) at a starting dose of 90 mg/m², during two consecutive procedures at a 4-6 week interval.
Trial: 30911664
Drug: High-dose oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxaliplatin during PIPAC
Trial: 30911859
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + chemotherapy (200 mg on day 1, cisplatin 80 mg/m)
Trial: 30911859
Drug: Pembrolizumab (monotherapy)
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (monotherapy)
Trial: 30911926
Drug: Extended-pulsed fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended-pulsed fidaxomicin (EPFX) 200 mg twice daily (days 1-5); once daily on alternate days (days 7-25)
Trial: 30911926
Drug: Vancomycin 125
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg four times daily (days 1-10)
Trial: 30913032
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue (SAT) distribution measurements at 15 standardized locations
Trial: 30913226
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 12 mg/kg/day BID
Trial: 30913226
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 18 mg/kg/day TID
Trial: 30913226
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 18 mg/kg/day BID
Trial: 30913226
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 12 mg/kg/day BID, 18 mg/kg/day BID, and 18 mg/kg/day TID
Trial: 30913226
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension
Trial: 30914274
Drug: FSH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH treatment (3-6 hours)
Trial: 30914274
Drug: Elevated FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated FSH (>11 U/L) in infertile men
Trial: 30914970
Drug: Novel nutraceutical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel nutraceutical compound containing red yeast rice, polymethoxyflavones, and antioxidants, dosage and duration not available
Trial: 30915029
Drug: Acipimox administration
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox administration with exercise
Trial: 30915112
Drug: Preoperative TG
RxNorm normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative TG levels in benign group (median 167.5 ng/mL)
Trial: 30915626
Drug: Phosphate-free formulation
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate-free formulation of etanercept (50 mg)
Trial: 30915626
Drug: Prior formulation
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior formulation of etanercept (50 mg)
Trial: 30915922
Drug: Atezolizumab (TECENTRIQ®)
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (TECENTRIQ®) plus chemotherapy (Abraxane; nab®-Paclitaxel)
Trial: 30915992
Drug: High-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose i.v. naloxone infusion (total dose 3.25 mg kg)
Trial: 30917689
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter-defibrillator shock at 65 J
Trial: 30917871
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interleukin-2 (HD IL-2)
Trial: 30917871
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interleukin-2 (HD IL-2) alone
Trial: 30918874
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of insulin doses normalized for body weight
Trial: 30920187
Drug: Current opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current opioid agonist treatment (buprenorphine maintenance)
Trial: 30921081
Drug: Apical suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apical suspension
Trial: 30921081
Drug: No apical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No apical suspension
Trial: 30922248
Drug: Icaritin 600
RxNorm normalized name: Icariin
DrugBank: Icariin (DB12052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin 600 or 800 mg b.i.d.
Trial: 30922276
Drug: Enemas, methylnaltrexone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enemas, methylnaltrexone, or 4-l polyethylene-glycol solution
Trial: 30922276
Drug: Morphine equivalent
RxNorm normalized name: paregoric 2 MG (as morphine equivalent) in 5 mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine equivalent daily dose
Trial: 30922805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pertuzumab, subcutaneous trastuzumab, and taxane chemotherapy
Trial: 30923464
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 μg/day) and Coenzyme Q10 (200 mg/day)
Trial: 30923820
Drug: anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 therapy (pembrolizumab or nivolumab)
Trial: 30924406
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccines (PCVs) - ≥1 dose ≥ age 2 months
Trial: 30924924
Drug: BRV (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV (100 mg, intravenous)
Trial: 30924924
Drug: BRV (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV (200 mg, intravenous)
Trial: 30924924
Drug: LEV (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV (1500 mg, intravenous)
Trial: 30924924
Drug: BRV (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV (50-100 mg, oral, twice-daily for 4 days)
Trial: 30924924
Drug: LEV (250-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV (250-600 mg, oral, 4 hours postdose)
Trial: 30924938
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 6'6'H2 glucose
Trial: 30926081
Drug: Decitabine 30
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 30 mg plus cedazuridine 100 mg
Trial: 30926081
Drug: Decitabine 40
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 40 mg plus cedazuridine 100 mg
Trial: 30927064
Drug: Higher-dairy diets
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dairy diets (Q4, 274-1429 g/day dairy)
Trial: 30928173
Drug: FSME-IMMUN vaccination
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSME-IMMUN vaccination after 3-dose primary immunization
Trial: 30928393
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of age, BMI, PlGF, and MMP9 for OSA identification
Trial: 30929188
Drug: Blephapad Combo
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blephapad Combo treatment arm (wet wipes with terpinen-4-ol and hyaluronic acid)
Trial: 30929188
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm (wet and warm gauze)
Trial: 30929188
Drug: Blephapad Combo
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blephapad Combo treatment arm
Trial: 30929225
Drug: Medical exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical exercise therapy for 3 months
Trial: 30929678
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 22.5-mg depot
Trial: 30929749
Drug: WHO 2015
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO 2015 guidelines for treatment eligibility
Trial: 30929749
Drug: EASL 2017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EASL 2017 guidelines for treatment eligibility
Trial: 30930133
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Insulin (RI) on TPN
Trial: 30930133
Drug: Glargine Insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine Insulin (GI)
Trial: 30932132
Drug: Participants meeting
RxNorm normalized name: Dolce and Gabbana Meet Your Flawless Matte Skin Duo KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants meeting the protein recommendation (0.8 g/kg/d)
Trial: 30932132
Drug: Participants not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants not meeting the protein recommendation (0.8 g/kg/d)
Trial: 30935383
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present.
Trial: 30935734
Drug: Anti-TNFα therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα therapy
Trial: 30936830
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Ticagrelor, dosage not specified, duration not specified
Trial: 30937138
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC) with a rapid home-based up-dosing schedule
Trial: 30937138
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC)
Trial: 30937138
Drug: Pre-seasonal treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-seasonal treatment initiation with SLIT
Trial: 30938688
Drug: Interactive Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Voice Response and Text Message (IVR-T) intervention including automated text messages or phone calls in English or Spanish, reminders for appointments, medication refills, and motivational messages; offered home blood pressure monitor.
Trial: 30938714
Drug: Conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning chemotherapy followed by CD19-targeted CAR T-cells (19-28z).
Trial: 30938714
Drug: Ibrutinib therapy
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib therapy at the time of autologous T-cell collection and/or CAR T-cell administration.
Trial: 30938714
Drug: Conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning chemotherapy and 19-28z CAR T-cells.
Trial: 30938874
Drug: Depressive symptoms,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depressive symptoms, self-esteem level, and types of treatment received
Trial: 30939086
Drug: Hypnosis-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis-based group intervention combining self-care and hypnosis; details on dosage and duration not available.
Trial: 30939489
Drug: EBR 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBR 50 mg plus GZR 50 mg once daily for 12 weeks